Aripiprazole CAS 129722-12-9 Purity >99.0% (HPLC) API
Baetsi ba Lihlahisoa tsa Lihlahisoa tsa Aripiprazole ka Bohloeki bo Phahameng
Aripiprazole API CAS 129722-12-9
1-(2,3-Dichlorophenyl)piperazine Hydrochloride CAS 119532-26-2
7-Hydroxy-3,4-Dihydro-2(1H)-Quinolinone CAS 22246-18-0
7-(4-Bromobutoxy)-3,4-Dihydro-2(1H)-Quinolinone CAS 129722-34-5
| Lebitso la Lik'hemik'hale | Aripiprazole |
| Litlhaloso tse tšoanang | 7-[4-[4-(2,3-Dichlorophenyl)-1-Piperazinyl]butoxy]-3,4-Dihydro-2(1H) -Quinolinone |
| Nomoro ea CAS | 129722-12-9 |
| Nomoro ea KAtse | RF-PI2270 |
| Boemo ba Setoko | Ka Setokong, Sekhahla sa Tlhahiso Ho fihlela ho Lithane |
| Foromo ea limolek'hule | Setšoantšo sa C23H27Cl2N3O2 |
| Boima ba Molek'hule | 448.39 |
| Solubility | Monyetla o sa qhibiliheng ka Metsing;Ha e qhibilihe ka har'a Methanol |
| Brand | Ruifu Chemical |
| Ntho | Litlhaloso |
| Ponahalo | Phofo ea Crystalline e tšoeu kapa e batlang e le tšoeu |
| Boitsebiso | Ka IR;Ka HPLC |
| Solubility | E qhibiliha ka Acetic Acid, E Hanyenyane Hanyenyane ka Ethanol |
| Melting Point | 136.0 ~ 140.0℃ |
| Tahlehelo ka ho Omisa | <0.50% |
| Masalla a ho Ignition | <0.10% |
| Litšepe tse boima | ≤20ppm |
| Metsoako e setseng | |
| Ethanol | ≤1000ppm |
| DMF | ≤200ppm |
| Lintho Tse Amanang | |
| Tšilafalo efe kapa efe e le 'Ngoe | <0.20% |
| Litšila ka Kakaretso | <1.00% |
| Mokhoa oa Bohloeki / Analysis | >99.0% (HPLC) |
| Tlhahlobo | 98.0%~102.0% (Motheong oa Anhydrous) |
| Meeli e Menyenyane | |
| Kakaretso ea Aerobic Microbial Count | ≤1000 cfu/g |
| Tomoso le hlobo li kopane | ≤100 cfu/g |
| E·Coli | Ho ba sieo |
| Ho Hlophisa Pathogen | Ho ba sieo |
| Tekanyetso ea Teko | Maemo a Khoebo |
| Tšebeliso | API;Antipsychotic |
Sephutheloana: Botlolo, 5kg / Aluminium tin, 25kg / Cardboard Drum, kapa ho latela tlhoko ea moreki
Boemo ba polokelo:Boloka ka lijaneng tse koetsoeng sebakeng se phodileng le se omileng;Sireletsa leseli le mongobo
Aripiprazole (CAS: 129722-12-9) ke mofuta o mocha oa lintho tse tsoang ho quinoline tse qhibilihang haholo ka lipid, litlamorao tsa eona tsa pharmacological ke hore ha se feela mohanyetsi oa postsynaptic dopamine D2 receptor, empa hape le presynaptic dopamine D2 receptor agonist, hape e ka khona. thabisa D1, D3, D4 receptors.Aripiprazole ke moloko oa bobeli oa atypical antipsychotic le anti-depressant e nang le karolo e itseng ea agonist ho dopamine D2 le li-receptor tsa serotonin 5-HT1A le ts'ebetso ea mohanyetsi ho li-receptor tsa serotonin 5-HT2A.Litekanyetso tsa Ki ke 0.34 nM, 0.8 nM, 1.7 nM, le 3.4 nM, ka ho latellana, bakeng sa dopamine D2 le D3, serotonin 5-HT1A le 5-HT2A receptors.Aripiprazole e sebelisoa bakeng sa kalafo ea schizophrenia le mathata a amanang le psychotic.Khamphani ea Bristol-Myers Squibb le Otsuka Pharmaceutical e phatlalalitse hore European Union e amohetse Abilify (Aripiprazole) kalafong ea lethathamo la schizophrenia.Schizophrenia e ama 1% ea baahi ba lefats'e, le ho feta ho bacha ba baholo.Schizophrenia e ama monahano, taolo ea maikutlo le bokhoni ba ho etsa liqeto tsa mokuli.Bakuli ba nang le schizophrenia-positive ba tla ba le matšoao a kang lipono le likhopolo-taba, bakuli ba nang le matšoao a mabe ke ho itokolla sechabeng, ho hloka liphetoho maikutlong.Ka 2002 FDA e amohetse Abilify bakeng sa kalafo ea schizophrenia, e nang le matla a litekanyetso tse hlano: 5 mg, 10 mg, 15 mg, 20 mg le 30 mg, ho tloha ha e amoheloa.
